Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

AbbVie has announced plans to evaluate HIV medicine Kaletra / Aluvia (lopinavir / ritonavir) as Covid-19 treatment.

The company entered into partnerships with health authorities and institutions in various countries to investigate the efficacy and antiviral activity of the medication.

Furthermore, the company is aiding in clinical studies and basic research of lopinavir / ritonavir.

It is coordinating with European health authorities, the US Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also allied with industry partners and the Innovative Medicines Initiative to research and identify targeted medicines against Covid-19.

AbbVie donated Aluvia to China in January for experimental use against the new viral disease. According to Chinese media reports, Kaletra / Aluvia is effective against Covid-19.

The company adds that it lacks access to Chinese clinical information to confirm the accuracy of these reports.

AbbVie chairman and CEO Richard Gonzalez said: “We are committed to helping in any way we can to address the Covid-19 public health crisis, which is why we responded quickly to the Chinese authorities’ request for Aluvia in late January.

“We are working with global health authorities to ensure we meet the need of Covid-19 patients, conduct the appropriate clinical trials to evaluate its efficacy and ensure uninterrupted supply of the drug Kaletra/Aluvia for HIV patients around the world.”

The company provided Kaletra / Aluvia as an investigational drug for Covid-19 treatment in various countries with immediate patient need.

Meanwhile, the company is also working to increase the medicine’s supply for HIV patients.

In a statement, AbbVie said: “AbbVie continues to closely monitor manufacturing and supply chain resources around the world and does not anticipate any disruption to its medicine supply as a result of Covid-19.”